PDCD1 and non-small cell lung carcinoma: However, in general, PD-1 inhibitors account for a higher incidence of all-grade (3.6% vs. 1.3%) and high-grade (1.1% vs. 0.4%) CIP than PD-L1 inhibitors based on a clinical trial of NSCLC (28).